Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexamethasone
Drug ID BADD_D00623
Description Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.[L10695] In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318]
Indications and Usage Dexamethasone and [ciprofloxacin] otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa.[L10698] Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Oral tablets are indicated for the treatment of multiple myeloma.[L10710] An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye.[L10719] Various ophthalmic formulations are indicated for inflammatory conditions of the eye.[L10704,L10707,L10713,L10716,L10722,L10725]
Marketing Status approved; investigational; vet_approved
ATC Code A01AC02; C05AA09; D07AB19; D07XB05; D10AA03; H02AB02; R01AD03; S01BA01; S01CB01; S02BA06; S03BA01
DrugBank ID DB01234
KEGG ID D00292
MeSH ID D003907
PubChem ID 5743
TTD Drug ID D0IT2G
NDC Product Code 80425-0328; 0009-5019; 22552-0039; 38779-0405; 0904-7266; 55154-4901; 63187-561; 67296-1496; 70518-2998; 70868-920; 0054-4183; 0054-8176; 0054-8181; 0054-8183; 0998-0615; 55718-133; 71161-138; 79572-012; 42195-490; 45865-989; 55154-4914; 68788-8223; 70382-204; 71205-012; 42291-155; 50090-0088; 60687-718; 60687-729; 64980-509; 68788-8467; 72189-383; 55289-582; 60219-2044; 67296-0326; 0054-4179; 0054-8179; 0054-8180; 72893-015; 55718-157; 65089-0045; 42195-127; 60219-2043; 63629-7850; 70954-402; 71205-013; 0054-4181; 0054-4182; 0054-4186; 71205-703; 71879-001; 46439-8765; 82298-111; 50090-6151; 61919-827; 63187-383; 63629-4129; 63629-7806; 68788-7267; 69306-111; 69306-114; 70518-3050; 70954-404; 0054-4184; 49452-2465; 0078-0925; 0023-3348; 61919-269; 68071-2744; 68788-8293; 0054-3177; 70954-403; 0054-8175; 71335-2108; 72189-254; 51552-0430; 51927-1081; 52128-170; 42195-721; 43063-266; 48102-051; 50090-0089; 54879-003; 60219-2056; 62135-114; 68788-7142; 70954-401; 0054-8174; 72189-468; 60722-3013; 0121-1814; 42195-121; 42195-149; 42195-221; 47781-914; 47781-916; 55700-961; 69306-112; 55289-903; 63629-3742; 66993-730; 67296-1837; 68071-2321; 0054-4180; 55718-156; 57582-031; 57582-931; 42195-270; 50090-6152; 51407-361
UNII 7S5I7G3JQL
Synonyms Dexamethasone | Methylfluorprednisolone | Hexadecadrol | Decameth | Decaspray | Dexasone | Dexpak | Maxidex | Millicorten | Oradexon | Decaject | Decaject-L.A. | Decaject L.A. | Hexadrol
Chemical Information
Molecular Formula C22H29FO5
CAS Registry Number 50-02-2
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Joint effusion15.01.02.0050.000145%
Keratitis06.04.02.0020.000581%
Keratopathy06.06.03.0070.000872%Not Available
Ketoacidosis14.01.01.0080.000218%Not Available
Lacrimation increased06.08.02.0040.002412%
Large intestine perforation12.02.03.005; 07.04.06.0050.000799%
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.0030.000436%
Learning disability19.21.05.0020.000509%Not Available
Lens dislocation12.01.04.019; 06.06.05.0040.000291%Not Available
Lenticular opacities06.06.01.0030.000291%Not Available
Lethargy17.02.04.003; 08.01.01.008; 19.04.04.004--
Leukaemoid reaction01.02.01.0010.000145%Not Available
Leukocytosis01.02.01.0020.000872%
Leukoderma23.05.02.001--Not Available
Leukoencephalopathy17.13.02.0030.000145%
Leukopenia01.02.02.0010.001598%Not Available
Logorrhoea19.19.02.001; 17.02.08.0060.000218%Not Available
Loss of consciousness17.02.04.0040.001816%Not Available
Lung consolidation22.01.02.0100.000218%Not Available
Lung disorder22.02.07.0010.000581%Not Available
Lung infiltration22.01.02.0040.000654%Not Available
Lymphadenopathy01.09.01.0020.000436%Not Available
Lymphocytosis01.02.01.0030.000145%Not Available
Lymphopenia01.02.02.0020.002252%Not Available
Macular degeneration06.09.03.0010.000218%Not Available
Macular oedema06.04.06.0050.001453%Not Available
Maculopathy06.09.03.0070.000145%Not Available
Malaise08.01.01.003--
Malignant melanoma23.08.01.001; 16.03.01.0010.000291%Not Available
Mania19.16.02.0020.001162%
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 26 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene